Loading stock data…
Arrowhead Pharmaceuticals, Inc. (ARWR)
$85.60-1.18 (-1.36%)
Market ClosedLast close Jul 24
Arrowhead Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arrowhead Pharmaceuticals, Inc. in the Healthcare sector is trading at $85.60 with a market capitalization of $10.0B. Wall Street consensus targets $102.91 (11 analysts), implying a +20.2% move over the next 12 months. The stock is currently near its 52-week high of $95.49, remaining 33.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $73.74M↓ | $264.03M↑ | $256.47M↑ | $27.77M↓ | $542.71M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$141.26M↓ | $40.81M↓ | $44.11M↑ | -$165.55M↓ | $381.20M |
| Net Income | -$132.73M↓ | $30.81M↑ | -$23.75M↑ | -$175.24M↓ | $370.44M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of ang...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.01%
Volume
Today's trading volume
1.81M
Recent News
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High
Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket.
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data
Chardan analyst Keay Nakae raised the firm's price target on Arrowhead to $115 from $90 and keeps a Buy rating on the shares.
Arrowhead Shares Soar on Strong Triglyceride Drug Data
Shares of Arrowhead Pharmaceuticals jumped 19% Wednesday after the company said its experimental drug, called plozasiran, sharply cut levels of triglycerides, a type of fat in the blood, in two late-stage trials aimed at patients with dangerously high levels of the fat. Plozasiran, given as a shot every three months, lowered triglycerides by as much as 81% after a year, compared with a drop of about 27% for patients on placebo. Arrowhead said it planned to ask the Food and Drug Administration by year-end to approve it for the larger population of patients with severe high triglycerides.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th